Stock Analysis, Dividends, Split History

AGIO / Agios Pharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)4,456.95
Enterprise Value ($M)4,130.50
Book Value ($M)865.59
Book Value / Share15.03
Price / Book5.15
NCAV ($M)628.46
NCAV / Share10.91
Price / NCAV6.97
Share Statistics
Preferred Stock Shares Outstanding 0
Common Stock Shares Outstanding 48,826,153
Common Shares Outstanding 57,326,741
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.84
Return on Assets (ROA)-0.51
Return on Equity (ROE)-0.88
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio10.75
Income Statement (mra) ($M)
Royalty Revenue1,937,000.00
Collaboration Revenue Revenue From Related Parties0.00
Collaboration Revenue Other Revenues0.00
Collaboration Revenue0.00
License And Services Revenue41,074,000.00
Revenue From Related Parties41,074,000.00
Operating Income-320.79
Net Income-314.67
Earnings Per Share Basic-6.75
Earnings Per Share Basic And Diluted-6.75
Earnings Per Share Diluted-6.75
Cash Flow Statement (mra) ($M)
Cash From Operations-285.23
Cash from Investing-57.91
Cash from Financing-57.91
Identifiers and Descriptors
Central Index Key (CIK)1439222
Related CUSIPS
00847X904 00847X954

Split History

Stock splits are used by Agios Pharmaceuticals, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

Related News Stories

Agios (AGIO) Q2 Loss Narrows, Revenues Surpass Estimates

2018-08-03 zacks
Agios Pharmaceuticals Inc. (AGIO - Free Report) incurred second-quarter 2018 loss of $1.19 per share, narrower than the Zacks Consensus Estimate of a loss of $1.62 and the year-ago loss of $1.78. (5-0)

Agios Pharmaceuticals, Inc. 2018 Q2 - Results - Earnings Call Slides

2018-08-02 seekingalpha
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with their 2018 Q2 earnings call. (3-0)

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q2 2018 Results - Earnings Call Transcript

2018-08-02 seekingalpha
Good morning, and welcome to the Agios' Second Quarter 2018 Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session at the end. Please be advised that this call is being recorded at Agios' request. (3-0)

What's in the Cards for Agios (AGIO) Stock in Q2 Earnings?

2018-07-30 zacks
Agios Pharmaceuticals, Inc. (AGIO - Free Report) is slated to report second-quarter 2018 results on Aug 2 before the market opens. (20-0)

Biotech Stock Roundup: Biogen Gains on Q2 Results, Agios Gets FDA Nod For Leukemia Drug

2018-07-25 zacks
While the last week was pretty low key for the biotech sector, with a few regulatory updates, the sector is back in focus as bigwig Biogen, Inc. (BIIB - Free Report) reported better-than-expected second-quarter results and also upped its guidance. Key regulatory updates include Gilead Sciences, Inc.’s (GILD - Free Report) collaboration with Gadeta and Agios Pharmaceuticals, Inc. (AGIO - Free Report) obtaining FDA approval for its leukemia drug. (7-1)

CUSIP: 00847X104